BioCentury
ARTICLE | Clinical News

Sol-Gel's acne candidate meets in Phase II

May 11, 2018 5:45 PM UTC

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily low- and high-dose topical cream TWIN (S6G5T) both met the three co-primary endpoints compared with vehicle in a Phase II trial in 726 patients with acne. Data from the double-blind, U.S. trial were presented at the American Academy of Dermatology meeting in San Diego.

On the first co-primary endpoint, 27.4% of patients who received low-dose TWIN and 39.7% of patients who received high-dose TWIN achieved an assessment of clear or almost clear with a ≥2-grade improvement in Investigator's Global Assessment (IGA) score at week 12 vs. 12.3% for vehicle (p=0.006 and p<0.001, respectively). On the other co-primary endpoints, low- and high-dose TWIN both significantly reduced mean absolute inflammatory (17 and 16.9 lesions, respectively, vs. 11.5 lesions, p<0.001 for both) and non-inflammatory (23.7 and 23.6 lesions, respectively, vs. 13.7 lesions, p<0.001 for both) lesion counts from baseline to week 12 vs. vehicle...

BCIQ Company Profiles

Sol-Gel Technologies Ltd.